Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Middle East Conflict Threatens Global Economic Stability, World Bank Warns 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
U.S. Markets Post Strong Weekly Gains Despite Middle East Tensions and Rising Energy Prices 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Asian Markets Retreat as Gulf Crisis Fuels Oil Surge and Inflation Fears 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Japan Consumer Confidence Drops Sharply Amid Rising Fuel Costs and Middle East Tensions 
China's Factory-Gate Prices Rise for First Time in Over Three Years Amid Global Cost Pressures 
China Set to Exit Deflation Cycle in Early 2026, ANZ Analysts Say 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Oil Prices Rebound as Hormuz Disruptions and Middle East Tensions Rattle Markets 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Abbott Nutrition said last weekend that it had reopened its Sturgis, Michigan plant to resume the production of baby formula. The company hopes that the nationwide shortage of milk will be addressed once it begins the normal production once again.
Abbott Nutrition was able to open its production facility in Michigan after the U.S. Food and Drug Administration (USFDA) had given it the go-ahead to do so. The permit was granted by the agency after the company met the initial requirements as part of a May 16 consent decree.
According to CNBC, Abbott Nutrition will now restart the production of its EleCare baby formula that has been formulated for children who have difficulties digesting other products. The company will also manufacture its other specialty milk and metabolic formulas for infants.
As the company is now able to begin production again, it is hoping to release the first batch of EleCare milk products by June 20. Currently, Abbott is still working to comply with the guidelines set for the resumption of production for its Similac milk line and other infant formulas.
“We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America,” Abbott’s spokesman said in a statement. “We will ramp production as quickly as we can while meeting all requirements.“
It was noted that the issue with the supply of baby formula began in the early stage of the COVID-19 pandemic. However, the situation got worse when Abbott Nutrition’s production facility in Michigan was ordered to close due to contamination. The plant was shut down in February following reports of illnesses in babies after consuming the company-made milk formulas, and two infants have died.
“The FDA is continuing to work diligently to ensure the safe resumption of production of infant formula at Abbott Nutrition’s Sturgis, Michigan, facility,” the USFDA commented with regards to Abbot’s plant reopening. “The agency expects that the measures and steps it is taking, and the potential for Abbott Nutrition’s Sturgis, Michigan, facility, to safely resume production in the near-term, will mean more and more infant formula is either on the way to or already on store shelves moving forward.”
